You've got something with encouraging results, something that could improve the lives of millions of people with Parkinson's. You would think that you'd try to get it to market as soon as possible. How naive of me.

Look at OxfordBioMedica's press release dated 10th January 2014

http://www.oxfordbiomedica.co.uk/pre...in-the-lancet/

Look at the "Next objectives" section:

"Oxford BioMedica is currently evaluating a more potent formulation of ProSavin®, called OXB-102, to ensure the greatest chance of success in future randomised studies. OXB-102 will also increase the commercial opportunity by offering extended patent protection and a relative reduction in cost of goods."

John